Innovation1 Biotech Inc.
IVBT · OTC
2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.33 | 0.00 | -0.00 | 0.03 |
| FCF Yield | -30.00% | -44.66% | -0.15% | -5.09% |
| EV / EBITDA | -6.62 | -5.29 | -4.05 | -18.51 |
| Quality | ||||
| ROIC | 5.49% | 6.03% | -6.29% | -14.83% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 0.51 | 0.59 | 0.01 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 224.12% | 224.12% | 224.12% | -100.00% |
| Free Cash Flow Growth | 1.74% | -461.56% | 85.80% | 9.32% |
| Safety | ||||
| Net Debt / EBITDA | -3.32 | -3.04 | -0.04 | -0.22 |
| Interest Coverage | -1.08 | -1.50 | 1.74 | -2.14 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -122,283.45 | -123,221.38 | -119,982.12 | -105,091.49 |